

Cereno Scientific – executive interview

In this interview, we speak with Dr Rahul Agrawal, chief medical officer and head of R&D at [Cereno Scientific](#), about the latest findings from the Expanded Access Programme (EAP) for the company's lead candidate, CS1, in pulmonary arterial hypertension (PAH). He discusses how investors should interpret the long-term safety and clinical observations in the context of the study's exploratory design, limited patient population and the progressive nature of PAH. Rahul explains why the data provide meaningful support for CS1's clinical profile, highlights its potential to complement existing PAH therapies, including sotatercept, and outlines how the EAP continues to strengthen the rationale for CS1 as a potential disease-modifying treatment. He also provides an update on preparations for the global Phase IIb trial and outlines the key development milestones investors should monitor over the coming months.

